To what extent is heart failure appropriately diagnosed and treated among patients hospitalized with COPD exacerbations, who are known to be at risk for HF?
All articles by Virginia A. Schad, PharmD, RPh
Researchers compared the incidence of intra-familial influenza transmission after treatment of the first family member with baloxavir marboxil vs oseltamivir.
Investigators assessed whether chronic hepatitis C virus infection is associated with a higher incidence of esophageal cancer.
Investigators assessed the efficacy of fecal microbiota transplantation vs medical therapy for the treatment of Clostridioides difficile infection.
Does convalescent plasma prevent worsening respiratory failure or death in patients with COVID-19 pneumonia?
Investigators assessed the safety and efficacy of two 1-week quadruple therapies given consecutively in patients with difficult-to-treat Helicobacter pylori infections.
Investigators assessed the relationship between passive smoking in children and adults with adult risk for fatty liver.
Researchers sought to develop and validate a high-sensitivity SARS-CoV-2 RT-PCR procedure for testing stool specimens.
Researchers studied whether combining FMT with lifestyle modifications could enhance the engraftment of favorable microbiota in patients with obesity and T2DM.
The study authors aimed to estimate the prevalence and critical determinants of
psychological distress among gastroenterologists during the COVID-19 pandemic.
Investigators assessed the outcomes of patients with coronavirus disease 2019 and liver injury.
Emerging evidence indicates that gastrointestinal and hepatic manifestations may play an important role in COVID-19, but their prevalence and significance remain unknown.
A team of investigators assessed whether extending the duration of treatment with direct-acting antiviral agents would improve the virologic response in individuals with hepatitis C virus infection who demonstrate slow response to therapy.
Opt-out, universal screening for hepatitis C virus (HCV) infection conducted in urban emergency departments revealed a high prevalence of anti-HCV in adult patients tested.
Exposure to, and infection with, hepatitis C virus (HCV) in infants may cause disparate effects on adaptive B cells and innate immune cells, such as myeloid cells and natural killer cells.
In the United States between 2005 and 2014, inpatient prevalence of HAV in kidney transplant recipients was 23.42 cases per 100,000 admissions, and hospitalization for HAV after kidney transplantation was associated with ICU stay.
Treatment with direct-acting antivirals (DAAs) for hepatitis C virus (HCV) appears to be associated with an early high incidence of hepatocellular carcinoma (HCC) in patients with undefined or nonmalignant nodules.
Glecaprevir/pibrentasvir therapy is effective and well tolerated in patients aged > 75 years with hepatitis C virus (HCV) infection.
Hepatitis B surface antigen loss after nucleos(t)ide analogue or peginterferon (Peg-IFN)-containing regimens is durable in most patients with chronic hepatitis B.
Front-line providers minimally could check HBV DNA and ALT during pregnancy to assess mother‐to‐child transmission risk but HBeAg is recommended to be included in the initial HBV evaluation to get a more comprehensive understanding of the patient’s HBV disease state.
Viral hepatitis causing concomitant acute pancreatitis is a rare entity and outcomes vary depending on the type of hepatitis virus.
Because after hepatitis B viral suppression the cause and intervention for elevated alanine aminotransferase is somewhat unknown, investigators conducted a real-world study.
Lenvervimab was well tolerated and reduced levels of HBsAg to below undetectable levels for up to 1 month in patients with chronic HBV infection.
Patients with HCV infection should receive DAA therapy even if they have alcohol use disorder, diabetes, cirrhosis, or hepatic encephalopathy.
HBsAg, interferon inducible protein-10, and hepatitis B core related antigen serum levels can be useful for the decisions and management of treatment discontinuation in non-cirrhotic white patients with HBeAg-negative chronic hepatitis B.
As emergency departments (EDs) are critical settings for hepatitis C care in the United States, investigators evaluated trends and characteristics of hepatitis C-associated ED visits from 2006 to 2014.
In a small patient cohort, researchers found that heart transplantation from donors who were hepatitis C virus-positive to recipients without the virus were successful.
In China, researchers investigate the sustained virologic response and safety profile of coblopasvir plus sofosbuvir taken once daily for 12 weeks among patients with HCV genotypes 1, 2, 3, or 6 infections, including individuals with compensated cirrhosis.
Using data from an Egyptian cohort, investigators sought to determine the safety and efficacy of adding epigallocatechin gallate to sofosbuvir plus daclatasvir with or without ribavirin to treat patients with chronic hepatitis C virus.
As direct-acting antiviral (DAA) treatment can lead to HBV re-activation, testing for HBV DNA along with anti-HBc antibodies in men who have sex with men and people who use drugs co-infected with hepatitis C virus is warranted prior to DAA-treatment.